Given that aberrant MEK/ERK activation is associated with resistance and relapses in pediatric ALL [35], our study provide a rationale to further evaluate the incorporation of drugs targeting NEDDylation either alone or in combination with agents that target the MEK/ERK signaling pathway as part of a multi-agent approach for ALL therapy. This evidence concerns the gene MAP2K7 and acute lymphoblastic leukemia.